Mini-review
The allometric approach for interspecies scaling of pharmacokinetic parameters

https://doi.org/10.1016/0742-8413(92)90003-PGet rights and content

Abstract

A long standing problem in pharmacokinetics and toxicology is the extrapolation and correlation between results obtained in different animal species and man. Animal data may be scaled-up to predict PPs in man using the allometric approach. The allometric approach is empirical, but easy, and is based on the fact that the underlying physiological processes such as blood flow, heartbeat duration, breath duration etc. are essentially physical and related to B. This approach is generally applicable to compounds that are essentially renally excreted. For substances that are highly extracted by the liver, Cltot is a function of the LBF among various species. Based on the concept of neoteny, use of brain weight affords a more correct approach to the scaling of Clint of low extraction ratio drugs.

By using the invariant pharmacokinetic time, the superficial differences in concentration-time profiles due to chronological time among different species are removed. Finally, as Boxenbaum (1984) has said “parameters to be scaled, independent variables, and the mathematical relationships used in the scaling process are all at the discretion of the investigator. There are no proper or improper approaches; the only limitations are those imposed by the investigator.”

References (39)

  • H. Boxenbaum

    Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin

    J. Pharmacokin. Biopharm.

    (1980)
  • H. Boxenbaum

    Interspecies scaling, allometry, physiologic time, and ground plan of pharmacokinetics

    J. Pharmacokin. Biopharm.

    (1982)
  • H. Boxenbaum

    Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm

    Drug Metab. Rev.

    (1984)
  • H. Boxenbaum et al.

    Interspecies pharmacokinetic scaling in reductionist and allometric paradigms

  • H. Boxenbaum et al.

    Physiological models, allometry, neoteny, space-time and pharmacokinetics

  • R.L. Dedrick et al.

    Interspecies correlation of plasma concentration history of methotrexate (NSC-740)

    Cancer Chemother. Rep. Part I.

    (1970)
  • C. Efthymiopoulos et al.

    Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic

    J. Antimicro. Chemother.

    (1991)
  • G. Franceschi et al.

    Synthesis and biological properties of sodium (5R, GS, 8R)-6α-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 2253 and FCE 22891

    J. Antibiotics

    (1983)
  • J.H. Gogerty

    Preclinical research evaluation: pharmacology; toxicology; drug metabolism

  • Cited by (64)

    • Application of a health risk assessment model for cattle exposed to pesticides in contaminated drinking waters: A study case from the Pampas region, Argentina

      2018, Chemosphere
      Citation Excerpt :

      Although the rat NOAEL was used as a surrogate toxicity endpoint in an equine risk assessment carried out by Schleier III et al. (2008), we otherwise preferred to extrapolate the missing cattle toxicological data from rodents and dogs, as done by Riviere et al. (1997), applying the allometric method because of the following advantages. This method is based on the premise that many physiologic parameters are a function of the size (body weight) of the animal species (Ritschel et al., 1992). The use of a fractional power of body weight to derive toxicologically equivalent doses across species is an accepted practice supported by literature (Sharma and McNeill, 2009; Wang and Prueksaritanont, 2010; USEPA, 2011; Moyer et al., 2014).

    • Xenograft models for preclinical drug testing: Implications for adrenocortical cancer

      2012, Molecular and Cellular Endocrinology
      Citation Excerpt :

      Animal data are scaled-up to predict pharmacokinetics and pharmacodynamics in men using this empirical allometric method. However, this approach can be generally used for compounds metabolized and excreted by the kidney (Ritschel et al., 1992). For compounds metabolized in the liver and excreted in the bile other models may allow a better prediction, taking into account physiological properties of the species and biochemical characteristics of the drugs (Poulin and Theil, 2002).

    • Interspecies scaling in pharmacokinetics: A novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo

      2012, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      In particular, West's group developed a model to explain the origin of quarter-power scaling laws and their use in determining metabolic rates when organism body sizes vary over large orders of magnitude.20,21 Another concept, interspecies scaling with invariant PK time, results in the removal of the differences in concentration–time profiles due to chronological time.22 Unfortunately, interspecies extrapolation with these simple scaling laws is not satisfactory because it does not account for fundamental biochemical mechanisms, but merely incorporates weight or size factors.

    View all citing articles on Scopus
    View full text